ZyVersa Therapeutics, Inc. (ZVSA): Nasdaq/NYSE listing notice — Nasdaq to delist ZyVersa Therapeutics common stock effective ~Sep 28, 2025

ZyVersa Therapeutics, Inc.

Nasdaq notified ZyVersa on Sept 14, 2025, of delisting; Form 25 to be filed on or about Sept 18, 2025.
Stock was suspended from Nasdaq on July 17, 2025; trading on OTCQB since July 28, 2025 under symbol ZVSA.
Delisting effective ten days after Form 25 filing; company cites failure to meet minimum bid price rule.
Company's common stock will continue trading on OTCQB without disruption.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

ZyVersa Therapeutics, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

dicating that the Panel had determined to delist the Company’s securities from Nasdaq and that trading in the Company’s securities would be suspended at the open of trading on July 17, 2025, due to the Company’s failure to regain compliance with the minimum bid price requirements under Listing Rule 5550(a)(2) . CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Current Report on Form 8-K (“Form 8-K”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Form 8-K that do not relate to matters of hi

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

ZyVersa Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-013968

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.